TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Private Advisor Group LLC

Private Advisor Group LLC lifted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 3.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,407 shares of the biopharmaceutical company’s stock after acquiring an additional 542 shares during the period. Private Advisor Group LLC’s holdings in TG Therapeutics were worth $337,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Opaleye Management Inc. grew its stake in TG Therapeutics by 2.9% during the 1st quarter. Opaleye Management Inc. now owns 2,280,000 shares of the biopharmaceutical company’s stock worth $34,679,000 after buying an additional 65,000 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of TG Therapeutics during the second quarter valued at $36,501,000. Hood River Capital Management LLC increased its holdings in shares of TG Therapeutics by 6.7% during the second quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock valued at $27,982,000 after purchasing an additional 98,892 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of TG Therapeutics during the second quarter valued at $10,423,000. Finally, Jacobs Levy Equity Management Inc. increased its holdings in shares of TG Therapeutics by 29.9% during the first quarter. Jacobs Levy Equity Management Inc. now owns 524,861 shares of the biopharmaceutical company’s stock valued at $7,983,000 after purchasing an additional 120,699 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. B. Riley raised their price target on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. The Goldman Sachs Group lifted their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday. HC Wainwright lifted their target price on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, TD Cowen began coverage on TG Therapeutics in a report on Tuesday, October 29th. They set a “buy” rating and a $50.00 target price on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

TG Therapeutics Trading Up 5.1 %

Shares of NASDAQ TGTX opened at $27.17 on Thursday. TG Therapeutics, Inc. has a one year low of $9.81 and a one year high of $27.67. The firm has a market capitalization of $4.21 billion, a PE ratio of -258.60 and a beta of 2.19. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58. The business has a 50-day moving average price of $23.57 and a two-hundred day moving average price of $20.26.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. During the same quarter in the previous year, the business posted $0.73 earnings per share. The company’s revenue was down 49.4% compared to the same quarter last year. As a group, analysts predict that TG Therapeutics, Inc. will post 0.13 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.